Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia

• Published in: São Paulo medical journal Vol. 124; no. 3; pp. 165 - 167
• Main Authors: Cordeiro, Quirino, Miguita, Karen, Miracca, Elisabete, Elkis, Hélio, Vallada, Homero
• Format: Journal Article
• Language: English; Portuguese
• Published: Brazil Associação Paulista de Medicina - APM 2006; Associação Paulista de Medicina
• Subjects: Alleles; Antipsychotic Agents - blood; Antipsychotic Agents - therapeutic use; Association; Chi-Square Distribution; Clozapine - therapeutic use; Dopamine; Genetic polymorphism; Genotype; Humans; Medicin och hälsovetenskap; MEDICINE, GENERAL & INTERNAL; Odds Ratio; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic - genetics; Receptors, Dopamine D3 - genetics; Retrospective Studies; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - genetics; Treatment Outcome; Pharmacogenetics; Associação; Esquizofrenia; Dopamine; Association; Dopamina; Genetic polymorphism; Polimorfismo genético; Schizophrenia; Farmacogenética
• ISSN: 1516-3180; 1806-9460; 1806-9460; 1516-3180
• DOI: 10.1590/s1516-31802006000300013

Typical antipsychotics have a high affinity for dopamine receptors. It is therefore of interest to investigate such loci in pharmacogenetic studies on psychosis. We investigated the hypothesis that Ser9Gly polymorphism of the DRD3 gene may play a role in the differences in individual response to typical antipsychotics between schizophrenic patients. The sample was composed of 53 good responders and 59 poor ones. No significant differences between the good and poor responders were found in the allelic distribution (good responders: Ser9 61.32%, Gly9 38.67%; poor responders: Ser9 64.40%, Gly9 35.59%; odds ratio, OR = 0.88, 0.49 < OR < 1.56; chi2 = 0.23, 1 degree of freedom, df, p = 0.63) and genotype distribution (good responders: Ser9/Ser9 37.73%, Ser9/Gly9 47.16%, Gly9/Gly9 15.09%; poor responders: Ser9/Ser9 42.37%, Ser9/Gly9 44.06%, Gly9/Gly9 13.55%; chi2 = 0.25, 2 df, p = 0.88). Nor was there any association with homozygosity (good responders: homozygous: 52.82%, heterozygous: 47.16%; poor responders: homozygous: 55.92%, heterozygous: 44.06%; odds ratio, OR = 0.88, 0.39 < OR < 1.99; chi2 = 0.11, 1 df, p = 0.74). The results did not support the hypothesis that Ser9Gly polymorphism of the DRD3 gene influences the response to typical antipsychotics in our sample of schizophrenics.